What Is GLP-1? Understanding the Hormone Behind the Headlines
If you have been following health news lately, you have almost certainly come across the term GLP-1. It is on the covers of magazines, trending on social media, and the subject of some of the most talked-about developments in medicine today. But most of what people read focuses on the medications — Ozempic, Wegovy, Mounjaro — without explaining what GLP-1 actually is, where it comes from, and what it does naturally inside your body.
GLP-1 stands for Glucagon-Like Peptide-1. It is a hormone — a chemical messenger — that your body produces naturally in specialised cells in your gut called L-cells, which line the small intestine and colon. Every time you eat a meal, your digestive system releases GLP-1 into your bloodstream as a direct response to food — particularly in response to carbohydrates and fats reaching your intestines.
"GLP-1 is not a new invention — it is a hormone your body has been making your entire life. The medications that are making global headlines simply mimic and amplify what this natural molecule already does."
— Understanding GLP-1 BiologyOnce released, GLP-1 travels through the bloodstream and binds to GLP-1 receptors — special docking sites found in the pancreas, the brain, the stomach, the heart, and several other organs. This hormone acts like a signal that tells your body: food has arrived, manage it efficiently. It does this through several coordinated actions that regulate blood sugar, hunger, and digestion simultaneously.
In a healthy person, GLP-1 is produced within minutes of eating and broken down very quickly — within 2–3 minutes — by an enzyme called DPP-4. This extremely short lifespan is why GLP-1 was difficult to use medically for decades. The medications that are now famous worldwide were developed specifically to solve this problem: they are designed to mimic GLP-1's effects but last much longer in the body — from 24 hours for daily injections to a full week for once-weekly formulations like semaglutide.
Key distinction to understand: There is natural GLP-1 — the hormone your own gut produces — and then there are GLP-1 receptor agonists (also called GLP-1 medications or GLP-1 drugs), which are pharmaceutical compounds that activate the same GLP-1 receptors. This blog discusses both: the natural hormone and how the medications that mimic it generally work.
How Does GLP-1 Work? The Body's Natural Blood Sugar and Appetite Regulator
To understand why GLP-1 medications have become so significant, you first need to understand what natural GLP-1 does — and why its actions matter so profoundly for weight management and blood sugar control. GLP-1 is often described as a multi-tasking hormone because it activates several different biological systems at the same time through a coordinated set of signals.
When GLP-1 reaches the pancreas after a meal, it signals the beta cells to release insulin — but only when blood sugar is elevated. This glucose-dependent mechanism is critical: it means GLP-1 does not cause insulin to be released when blood sugar is already low, reducing the risk of hypoglycaemia (dangerously low blood sugar) that some other diabetes medications carry.
GLP-1 simultaneously signals the alpha cells of the pancreas to reduce their production of glucagon — a hormone that raises blood sugar by prompting the liver to release stored glucose. By suppressing glucagon after a meal, GLP-1 prevents unnecessary blood sugar spikes and keeps glucose levels more stable throughout the day.
GLP-1 slows the rate at which food moves from the stomach into the small intestine — a process called gastric emptying. This means food stays in your stomach longer, you feel full more quickly, and the rise in blood sugar after eating is more gradual and manageable. This is one of the primary reasons why people on GLP-1 medications report eating significantly less.
GLP-1 receptors exist in the hypothalamus and brainstem — regions that control hunger, satiety, and the brain's reward response to food. When GLP-1 activates these receptors, it sends a clear signal: you are full, stop eating. Many people on GLP-1 medications describe experiencing dramatic reductions in what they call "food noise" — the constant background preoccupation with food and cravings that those with obesity or binge eating patterns often experience.
Beyond the pancreas and brain, GLP-1 receptors are found in the heart, kidneys, liver, and lungs. This wide distribution explains why GLP-1 medications are being studied and used for a growing range of conditions beyond diabetes and obesity — including cardiovascular disease, metabolic liver conditions, and sleep apnoea. Understanding this broad receptor distribution is key to understanding both the benefits and the side effects of GLP-1 medications.
The GLP-1 Pathway: From Gut to Brain
Here is how the GLP-1 signal travels through your body after a meal:
Why does this matter for weight management? The combination of slowed digestion (you feel full longer), reduced appetite signals to the brain (you want to eat less), and improved blood sugar control (fewer energy crashes and cravings) creates a powerful metabolic environment that naturally leads to reduced calorie intake — without the willpower struggle that traditional dieting requires. This is the fundamental reason GLP-1 medications have attracted so much attention.
GLP-1 Medications: Ozempic, Wegovy, Mounjaro, Zepbound — What's the Difference?
The most searched names in health right now — Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda — are all part of the GLP-1 medication family. They all work by activating GLP-1 receptors, but they differ in their active ingredients, approved uses, dosing schedules, and in some cases, which additional hormones they also target. Here is a clear overview:
A key distinction worth understanding is between Ozempic and Wegovy: both contain semaglutide, but Ozempic is approved for managing type 2 diabetes and Wegovy is approved specifically for obesity treatment. The same active ingredient, same manufacturer (Novo Nordisk), but different doses and different FDA approvals. Ozempic's use for weight loss in people without diabetes is technically "off-label" — legal for doctors to prescribe, but not the medication's primary approved purpose. This nuance is often lost in media coverage.
Similarly, Mounjaro and Zepbound both contain tirzepatide from Eli Lilly. Tirzepatide is sometimes called a "dual agonist" because it targets two hormones — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — simultaneously. This dual action has shown even greater effectiveness for blood sugar control and weight reduction in clinical trials compared to single GLP-1 agonists.
On compounded GLP-1 medications: Due to supply shortages of branded GLP-1 drugs, "compounded" versions of semaglutide and tirzepatide became widely available through telehealth platforms. These are not FDA-approved versions of the original drugs. Regulatory bodies including the FDA have issued warnings about compounded versions and their safety profiles, and as of 2025, the FDA has taken steps to limit compounding of these substances as brand supply has improved.
Who Are GLP-1 Medications Generally Prescribed For?
One of the most common questions people search is: "Am I a candidate for GLP-1 medications?" The general eligibility criteria are centred on body mass index (BMI) and associated health conditions. These are general informational guidelines — always consult a qualified doctor for personal medical advice.
Important: The information above is general in nature. GLP-1 medications are prescription drugs that require a full medical evaluation, discussion of your health history, and ongoing monitoring by a qualified healthcare provider. Do not use social media, celebrity endorsements, or online searches as the basis for starting these medications. Always consult a doctor.
GLP-1 Side Effects: Common, Less Common, Rare & the "Hidden" Ones People Are Talking About
One of the most searched questions about GLP-1 medications is: "What are the side effects of Ozempic / Wegovy / Mounjaro?" Side effects exist on a spectrum — from very common and generally manageable, to rare but serious. Understanding this spectrum is important for anyone considering or currently using these medications.
The most significant thing to know about GLP-1 side effects is that they are closely tied to the medication's mechanism of action. Because GLP-1 medications powerfully slow digestion and act strongly on the gastrointestinal tract, most side effects are gastrointestinal in nature — particularly when starting treatment or when the dose is increased. For many people, these side effects are worst in the first few weeks and improve significantly over time as the body adjusts.
- Nausea — the most frequently reported; often worst when starting
- Vomiting — usually accompanies nausea, especially initially
- Diarrhoea — loose stools, particularly in the first weeks
- Constipation — more common as treatment continues
- Stomach pain and cramping
- Bloating and gas / flatulence
- Acid reflux / heartburn
- Decreased appetite (intended effect, sometimes excessive)
- Burping
- Fatigue and low energy — especially in the early weeks
- Headaches
- Dizziness
- Hair loss — linked to rapid weight loss (telogen effluvium), not the drug directly
- "Ozempic face" — facial sagging from rapid fat loss
- Muscle loss — weight lost may include lean muscle if protein intake is insufficient
- Injection site reactions — redness, swelling, or itching at the injection site
- Low blood sugar (hypoglycaemia) — more likely when combined with other diabetes medications
- Pancreatitis — inflammation of the pancreas; seek immediate care if severe abdominal pain occurs
- Gallstones / gallbladder disease — linked to rapid weight loss
- Kidney problems — dehydration from vomiting/diarrhoea may worsen kidney function
- Thyroid tumours — warning based on animal studies; not established in humans
- Severe allergic reactions — rare; discontinue and seek care immediately
- Vision changes — some reports of diabetic retinopathy worsening
- Menstrual irregularities — reported widely by women on Reddit and other forums
- Temperature sensitivity — chills, hot flashes reported in real-world use
- Mood and mental health changes — some users report anxiety, depression, or emotional numbness
- Sleep disruption
- Reduced interest in alcohol — widely reported, being studied formally
- Reduced desire for addictive behaviours — potential therapeutic area being explored
"GLP-1 medication side effects are real, but for most people they are temporary. The key is starting at the lowest dose and increasing slowly — and always under medical supervision."
— General Guidance on GLP-1 TolerabilityManaging GLP-1 Side Effects: General Tips
For the most common GI side effects of GLP-1 medications, several practical approaches are commonly recommended by healthcare providers. These include eating smaller, more frequent meals rather than large portions (since the stomach empties more slowly on these medications, overeating becomes uncomfortable quickly). Choosing bland, lower-fat foods on days following injections can reduce nausea. Staying well hydrated is essential — particularly important because diarrhoea and vomiting carry dehydration risk. Eating slowly and stopping as soon as fullness is felt prevents the discomfort that occurs when eating past the medication-enhanced satiety signal.
The "food noise" effect: One of the most striking things people on GLP-1 medications report is a dramatic reduction in what is colloquially called "food noise" — the constant mental preoccupation with food, cravings, and the next meal. For people who have struggled with emotional eating, binge eating, or food obsession for years, this reduction can feel profoundly life-changing. It is one of the effects that goes beyond simple calorie reduction and speaks to the medication's action on the brain's reward centres.
Natural GLP-1: How to Boost Your Body's Own GLP-1 Hormone Without Medication
Before GLP-1 receptor agonist medications existed, your gut was already producing this hormone every time you ate. Certain foods and lifestyle habits have been shown to stimulate greater natural GLP-1 release — which supports better blood sugar control, improved satiety, and a healthier metabolism without pharmaceutical intervention. While this natural GLP-1 boost is nowhere near as dramatic or sustained as medication, it is a meaningful part of a healthy lifestyle and relevant to anyone interested in metabolic wellness.
The lifestyle and GLP-1 medication synergy: For people who are prescribed GLP-1 medications, maintaining a high-protein, high-fibre diet and regular exercise is especially important — not just to amplify the medication's effects, but to protect against muscle loss (which occurs with rapid weight reduction) and to support long-term weight maintenance, which requires lifestyle habits regardless of how effective the medication is.
GLP-1 FAQs: The Questions Everyone Is Searching Right Now
Both Ozempic and Wegovy contain the same active ingredient — semaglutide — manufactured by Novo Nordisk. The key difference is their approved use and dose. Ozempic is approved for the management of type 2 diabetes and is administered in lower doses (0.5mg to 2mg weekly). Wegovy is approved specifically for obesity management and uses a higher maintenance dose (2.4mg weekly). Using Ozempic specifically for weight loss without a diabetes diagnosis is technically off-label prescribing.
This is one of the most commonly asked questions. When GLP-1 medications are stopped, the hormone-mimicking effects end. For many people, appetite returns to its previous level, food noise resumes, and without the medication's metabolic support, weight tends to return over time — particularly if lifestyle habits (diet, exercise) have not been well established during the treatment period. This is why GLP-1 medications are generally considered a long-term rather than short-term commitment, and why lifestyle change alongside medication use is emphasised by healthcare providers.
Yes — and this is a rapidly developing area. Rybelsus (oral semaglutide) has been available for type 2 diabetes management for several years. In January 2025, the FDA approved an oral form of Wegovy (oral semaglutide at higher dose) specifically for obesity. In April 2025, the FDA approved orforglipron (Eli Lilly) — a daily pill for weight management. Oral versions are generally less effective than injections at equivalent doses, but the convenience factor is significant and is expected to dramatically expand access.
This is a legitimate concern. Weight loss from GLP-1 medications — like most forms of significant calorie restriction — includes both fat and lean muscle mass. Estimates suggest that around 25–39% of weight lost on GLP-1 medications can be lean mass (muscle), depending on diet and exercise during treatment. This is why maintaining high protein intake (targeting 1.2–1.6g per kg of body weight) and engaging in regular strength training are strongly recommended alongside GLP-1 medication use.
GLP-1 medications including semaglutide (Ozempic) and liraglutide (Victoza) are available in India as prescription medications, primarily indicated for type 2 diabetes management. Wegovy (the higher-dose obesity formulation) has had more limited availability in India compared to Western markets. Cost is a significant barrier — these medications are expensive and generally not covered by standard health insurance in India. Anyone interested should consult a qualified endocrinologist or diabetologist for appropriate guidance.
This is one of the most intriguing and widely discussed "side effects" of GLP-1 medications. Many people report a dramatic reduction in their desire for alcohol after starting GLP-1 treatment. This appears to be related to the medication's action on the brain's reward and dopamine systems — the same pathways involved in addictive behaviour more broadly. Formal clinical trials are currently underway to investigate GLP-1 medications as potential treatments for alcohol use disorder, substance dependence, and other compulsive behaviours. Results are expected in the coming years.
"Ozempic face" is a colloquial term for the facial sagging, hollowness, and loss of facial volume that can occur with rapid, significant weight loss — not just from semaglutide specifically, but from any method that produces rapid fat reduction. When the face loses fat quickly, skin may not contract as fast, leading to a gaunt or aged appearance. This is more pronounced in older individuals. It is not unique to GLP-1 medications and is essentially the same phenomenon seen after any rapid weight loss, including bariatric surgery.
What You Need to Know About GLP-1 — The Short Version
GLP-1 is one of the most significant topics in medicine and public health right now — and the speed at which it has entered mainstream conversation has left many people searching for clear, reliable information. Here is the short version of everything covered in this blog:
